ECCMID 2018 meeting report: the continuing clinical challenge of nontuberculous mycobacteria lung disease.

Abstract

Future MicrobiologyVol. 13, No. 12 Conference ReportECCMID 2018 meeting report: the continuing clinical challenge of nontuberculous mycobacteria lung diseaseIan MasonIan Mason*Author for correspondence: E-mail Address: idmaddress@ntlworld.com Freelance Medical WriterSearch for more papers by this authorPublished Online:26 Sep 2018https://doi.org/10.2217/fmb-2018-0171AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: ECCMIDlung diseasemycobacterianontuberculousNTMReferences1 Wetzstein N, Hogardt M, Wichelhaus T et al. Prevalence of infection and colonization with nontuberculous mycobacteria in a tertiary care center. Presented at: The 28th European Congress of Clinical Microbiology and Infectious Diseases. Madrid, Spain, 21–24 April 2018 (Abstract P1615).Google Scholar2 Marvin Ruth M, Sangen J, Pennings L et al. Bedaquiline-clofazimine is an interesting backbone for new regimens to treat nontuberculous mycobacterial disease. Presented at: The 28th European Congress of Clinical Microbiology and Infectious Diseases. Madrid, Spain, 21–24 April 2018 (Abstract O0494).Google Scholar3 Sangen J, Marvin Ruth M, Zweijpfenning S et al. Can minocycline add activity to treatment regimens for nontuberculous mycobacterial disease? Presented at: The 28th European Congress of Clinical Microbiology and Infectious Diseases. Madrid, Spain, 21–24 April 2018 (Abstract O0495).Google Scholar4 Interview with Dr Nils Wetzstein. Presented at: European Congress of Clinical Microbiology and Infectious Diseases. Madrid, Spain, 21–24 April 2018. Google Scholar5 Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175(4), 367–416 (2007).Crossref, Medline, CAS, Google Scholar6 Jankovic Makek M, Sabol I, Zmak L et al. Treatment outcomes and 5-year survival in patients with nontuberculous pulmonary disease, data from Croatian national registry. Presented at: The 28th European Congress of Clinical Microbiology and Infectious Diseases. Madrid, Spain, 21–24 April 2018 (Abstract O0490).Google Scholar7 Marras T, Mirsaeidi M, Chou E et al. Rate of all-cause hospitalization at year 2 between treatment groups following diagnosis of nontuberculous mycobacterial lung disease in the US. Presented at: The 28th European Congress of Clinical Microbiology and Infectious Diseases. Madrid, Spain, 21–24 April 2018 (Abstract P1596).Google Scholar8 Vianna J, Ramis I, Dienefer B et al. Tetrahydropyridine as drug efflux inhibitor in Mycobacterium abscessus. Presented at: The 28th European Congress of Clinical Microbiology and Infectious Diseases. Madrid, Spain, 21–24 April 2018 (Abstract P1586).Google Scholar9 Van Der Laan R, Obradovic M. Mortality in patients with Mycobacterium avium complex lung disease - a review of the published literature. Presented at: The 28th European Congress of Clinical Microbiology and Infectious Diseases. Madrid, Spain, 21–24 April 2018 (Abstract P1595).Google ScholarFiguresReferencesRelatedDetails Vol. 13, No. 12 Follow us on social media for the latest updates Metrics Downloaded 46 times History Received 4 June 2018 Accepted 28 June 2018 Published online 26 September 2018 Published in print September 2018 Information© 2018 Future Medicine LtdKeywordsECCMIDlung diseasemycobacterianontuberculousNTMFinancial & competing interests disclosureThis meeting report was funded by Insmed. The authors have no other relevant affiliations or financialinvolvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download